ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Prognostic significance of HALP score in İdiopathic Pulmonary Fibrosis-related mortality.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can the Prognostic Nutritional Index Be a Predictor of Acute Exacerbation of Idiopathic Pulmonary Fibrosis?Biomedicines · 2026Article
- Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2026Article
- Comparative Evaluation of Systemic Inflammatory Indices in Bronchiectasis: Identification of Exacerbation Phenotype.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTo investigate the prognostic value of the HALP (Hemoglobin, Albumin, Lymphocyte, and Platelet) score for mortality in patients with Idiopathic Pulmonary Fibrosis (IPF).
methodsFrom November 2020, 39 patients with IPF were followed for a duration of 3 years. At the end of 3 years, the relationship between the initial HALP score and mortality was investigated.
resultsThirty-nine patients diagnosed with IPF were included in the study, 30 of whom were male. The average age of all patients was 68.79±7.08. At the end of the three-year follow-up period, 12 patients (33.3%) had died. When comparing patients who died and those who survived at the end of three years; significant differences were found in age, neutrophil, albumin, HALP score, FEV1%, FVC%, DLCO%, GAP score, and 6 MWD. ROC analysis for the HALP score's predictive value for mortality yielded an AUC of 0.743 and p=0.011. For a cut-off value of HALP≤30.5, p=0.01, sensitivity and specificity were 61.54% and 92.31%, respectively. Multivariate analysis for predicting mortality found HALP≤30.50 as a significant risk factor (p=0.046). An increase of one monad at the HALP cut-off (≤30.50) score level reduced the risk of death by 9.57 times. It was observed that FVC%, DLCO% and 6 MWD were not risk factors in predicting mortality. (p=0.30, p=0.08, p=0.07).
conclusionsOur study suggests that the HALP score may serve as a negative prognostic biomarker that can be used to predict mortality in cases with IPF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.